Table 1.
COVID-19 patients | Male 187 (47) | Female 211 (53) | Total (398) | p-Value |
---|---|---|---|---|
Age (years) | 39.3 ± 17.0 | 37.9 ± 16.6 | 38.6 ± 16.8 | 0.711 |
Day to symptom (days) | 8 ± 8.1 | 4.8 ± 3.0 | 5.4 ± 5.0 (101) | 0.05 |
Symptom to diagnosis (days.) | 7.4 ± 5.6 | 7.5 ± 5.6 | 7.5 ± 5.6 (374) | 0.193 |
Indigenous n (%) | 25 (13.4) | 29 (13.7) | 54 (13.6) | 0.913 |
Imported: Europe | 78 (41.7) | 88 (41.7) | 166 (41.7) | 0.439 |
Imported: America | 41 (21.9) | 54 (25.6) | 95 (23.9) | |
Imported: Asia | 32 (17.1) | 36 (17.1) | 68 (17) | |
Imported: Africa | 9 (4.8) | 3 (1.4) | 12 (3) | |
Imported: Oceania | 2 (1.1) | 1 (0.5) | 3 (0.8) | |
Test at airport | 49 (26.2) | 58 (27.5) | 107 | 0.773 |
Mortality (%) | 6 (3.2) | 1 (0.5) | 7 (1.8) | 0.038∗ |
ICU admission (%) | 3 (1.6) | 0 (0) | 3 (0.8) | 0.065 |
Other diseases | ||||
DM (%) | 2 (1.1) | 0 (0) | 2 (0.5) | 0.132 |
HTN (%) | 3 (1.6) | 1 (0.5) | 4 (1.0) | 0.259 |
Uremia (%) | 1 (0.5) | 0 (0) | 1 (0.3) | 0.288 |
Lung infiltration (%) | 18 (9.6) | 16 (7.6) | 34 (8.5) | 0.467 |
Symptoms | ||||
Cough (%) | 80 (42.8) | 90 (42.3) | 170 (42.7) | 0.568 |
Fever (%) | 73 (39.0) | 86 (40.8) | 159 (39.9) | 0.726 |
Sore throat (%) | 54 (28.9) | 53 (25.1) | 107 (26.9) | 0.399 |
Rhinorrhoea (%) | 39 (20.1) | 60 (28.4) | 99 (24.9) | 0.083 |
Malaise (%) | 30 (16.0) | 25 (11.8) | 55 (13.8) | 0.226 |
Nasal stuffiness (%) | 20 (10.7) | 31 (14.7) | 51 (12.8) | 0.234 |
Muscle pain (%) | 27 (14.4) | 21 (10.0) | 48 (12.1) | 0.170 |
Anosmia (%) | 18 (9.6) | 29 (13.7) | 47 (11.8) | 0.204 |
Headache (%) | 20 (10.7) | 14 (6.6) | 34 (8.5) | 0.148 |
Diarrhoea (%) | 14 (7.5) | 17 (8.1) | 31 (7.8) | 0.832 |
Dysgeusia (%) | 10 (5.3) | 12 (5.7) | 22 (5.5) | 0.882 |
Chest pain (%) | 9 (4.8) | 10 (4.7) | 19 (4.8) | 0.937 |
SOB (%) | 6 (3.2) | 9 (4.3) | 15 (3.8) | 0.581 |
Asymptomatic (%) | 10 (5.3) | 7 (3.3) | 17 (4.3) | 0.318 |
All data are in form of n (%).
DM, diabetes mellitus; SOB, shortness of breath.